Jonathan Cleaver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan Cleaver has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Richard James
From Gastroenterology (J. Coenen), Imperial College Healthcare NHS Trust, London; and Departments of Neurology (J. Cleaver, G.C.) and Neuroradiology (R.J.), Royal United Hospital Bath NHS Trust, UK
5 shared publicationsGurjit Chohan
From Gastroenterology (J. Coenen), Imperial College Healthcare NHS Trust, London; and Departments of Neurology (J. Cleaver, G.C.) and Neuroradiology (R.J.), Royal United Hospital Bath NHS Trust, UK
4 shared publications- Adam E. Handel
Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford , Oxford, OX3 9DU
3 shared publications - Sarosh R. Irani
Department of Neurology Mayo Clinic Jacksonville Florida USA
3 shared publications - Hamish Duncan Morrison
Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, United Kingdom
2 shared publications Hamish Morrison
Neurology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in Journal of Infection
Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies
- 12 October 2026
- Published by Elsevier in Journal of Infection
Open AccessManagement of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies
- 13 March 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (2) , 198-199
Mapping Practical Neurology articles to the Neurology Specialty Certificate Examination curriculum
- 13 March 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (2) , 198-199
Mapping Practical Neurology articles to the Neurology Specialty Certificate Examination curriculum
- Top Cited PapersOpen Access
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (2) , e200540
Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis
Seronegative autoimmune encephalitis (AE), defined by an appropriate clinical phenotype in the absence of known neuronal autoantibodies, poses diagnostic and therapeutic challenges due to clinical heterogeneity and lack of definitive biomarkers. We conducted a systematic review and meta-analysis of individual patient data to characterize the phenotypes, treatment responses, and prognostic factors in seronegative AE. We included 213 cases from 30 studies published between 2014 and 2024 and 11 from a local cohort meeting Graus criteria for seronegative AE. We extracted details on clinical and paraclinical features, immunotherapy, and outcomes measured via the modified Rankin Scale (mRS) and Clinical Assessment Scale for Autoimmune Encephalitis (CASE). Multivariate regression and dimensionality reduction analyses identified prognostic markers. Of 224 patients (median age 49 years, 50.9% male), 72 (32.1%) had limbic encephalitis (LE) and 152 (67.9%) had antibody-negative probable AE (ANPRA). Good outcome (mRS score ≤2) was more common in LE (49/72, 68.1%) than in ANPRA (76/154, 50.0%) (p < 0.05). Delayed immunotherapy was associated with an increased risk of poor outcome. Additional predictors of poor prognosis included age older than 60 years, the ANPRA subtype, an underlying tumor, striatocapsular or thalamic involvement on MRI, and presentation with refractory status epilepticus. Dimensionality and clustering analysis identified heterogeneity among seronegative AE, with 3 distinct subtypes. Seronegative AE comprises clinically and prognostically distinct subtypes. Early immunotherapy is the key modifiable factor influencing outcome. We advocate for biomarker discovery and prospective, systematically reported cohort studies to improve stratification and treatment strategies in this diagnostically challenging population.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (2) , e200540
Top Cited PapersOpen AccessSystematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis
Seronegative autoimmune encephalitis (AE), defined by an appropriate clinical phenotype in the absence of known neuronal autoantibodies, poses diagnostic and therapeutic challenges due to clinical heterogeneity and lack of definitive biomarkers. We conducted a systematic review and meta-analysis of individual patient data to characterize the phenotypes, treatment responses, and prognostic factors in seronegative AE. We included 213 cases from 30 studies published between 2014 and 2024 and 11 from a local cohort meeting Graus criteria for seronegative AE. We extracted details on clinical and paraclinical features, immunotherapy, and outcomes measured via the modified Rankin Scale (mRS) and Clinical Assessment Scale for Autoimmune Encephalitis (CASE). Multivariate regression and dimensionality reduction analyses identified prognostic markers. Of 224 patients (median age 49 years, 50.9% male), 72 (32.1%) had limbic encephalitis (LE) and 152 (67.9%) had antibody-negative probable AE (ANPRA). Good outcome (mRS score ≤2) was more common in LE (49/72, 68.1%) than in ANPRA (76/154, 50.0%) (p < 0.05). Delayed immunotherapy was associated with an increased risk of poor outcome. Additional predictors of poor prognosis included age older than 60 years, the ANPRA subtype, an underlying tumor, striatocapsular or thalamic involvement on MRI, and presentation with refractory status epilepticus. Dimensionality and clustering analysis identified heterogeneity among seronegative AE, with 3 distinct subtypes. Seronegative AE comprises clinically and prognostically distinct subtypes. Early immunotherapy is the key modifiable factor influencing outcome. We advocate for biomarker discovery and prospective, systematically reported cohort studies to improve stratification and treatment strategies in this diagnostically challenging population.
- Open Access
- 6 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106566
Clinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis: A systematic review and meta-analysis
- 6 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106566
Open AccessClinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis: A systematic review and meta-analysis
- 8 July 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 120, 554-556
Hunting the origin and source of NR1-directed IgGs in patients with encephalitis
- 8 July 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 120, 554-556
Hunting the origin and source of NR1-directed IgGs in patients with encephalitis
- Open Access
- 13 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (4) , 1130-1148
The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity
Herpes simplex virus encephalitis (HSE) is the leading cause of non-epidemic encephalitis in the developed world and, despite antiviral therapy, mortality and morbidity is high. The emergence of post-HSE autoimmune encephalitis reveals a new immunological paradigm in autoantibody-mediated disease. A reductionist evaluation of the immunobiological mechanisms in HSE is crucial to dissect the origins of post-viral autoimmunity and supply rational approaches to the selection of immunotherapeutics. Herein, we review the latest evidence behind the phenotypic progression and underlying immunobiology of HSE including the cytokine/chemokine environment, the role of pathogen-recognition receptors, T- and B-cell immunity and relevant inborn errors of immunity. Second, we provide a contemporary review of published patients with post-HSE autoimmune encephalitis from a combined cohort of 110 patients. Third, we integrate novel mechanisms of autoimmunization in deep cervical lymph nodes to explore hypotheses around post-HSE autoimmune encephalitis and challenge these against mechanisms of molecular mimicry and others. Finally, we explore translational concepts where neuroglial surface autoantibodies have been observed with other neuroinfectious diseases and those that generate brain damage including traumatic brain injury, ischaemic stroke and neurodegenerative disease. Overall, the clinical and immunological landscape of HSE is an important and evolving field, from which precision immunotherapeutics could soon emerge.
- 13 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (4) , 1130-1148
Open AccessThe immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity
Herpes simplex virus encephalitis (HSE) is the leading cause of non-epidemic encephalitis in the developed world and, despite antiviral therapy, mortality and morbidity is high. The emergence of post-HSE autoimmune encephalitis reveals a new immunological paradigm in autoantibody-mediated disease. A reductionist evaluation of the immunobiological mechanisms in HSE is crucial to dissect the origins of post-viral autoimmunity and supply rational approaches to the selection of immunotherapeutics. Herein, we review the latest evidence behind the phenotypic progression and underlying immunobiology of HSE including the cytokine/chemokine environment, the role of pathogen-recognition receptors, T- and B-cell immunity and relevant inborn errors of immunity. Second, we provide a contemporary review of published patients with post-HSE autoimmune encephalitis from a combined cohort of 110 patients. Third, we integrate novel mechanisms of autoimmunization in deep cervical lymph nodes to explore hypotheses around post-HSE autoimmune encephalitis and challenge these against mechanisms of molecular mimicry and others. Finally, we explore translational concepts where neuroglial surface autoantibodies have been observed with other neuroinfectious diseases and those that generate brain damage including traumatic brain injury, ischaemic stroke and neurodegenerative disease. Overall, the clinical and immunological landscape of HSE is an important and evolving field, from which precision immunotherapeutics could soon emerge.
- 25 October 2022
- Published by BMJ in Practical Neurology
- Vol. 23 (2) , 164-165
Orthostatic dysarthria in myasthenia gravis
He showed pronounced flaccid nasal dysarthria throughout the consultation while sitting. To facilitate conversation, he asked to lie supine, which he had learnt could alleviate such difficulties. While supine, he maintained a marked improvement in speech with less nasal escape.
- 25 October 2022
- Published by BMJ in Practical Neurology
- Vol. 23 (2) , 164-165
Orthostatic dysarthria in myasthenia gravis
He showed pronounced flaccid nasal dysarthria throughout the consultation while sitting. To facilitate conversation, he asked to lie supine, which he had learnt could alleviate such difficulties. While supine, he maintained a marked improvement in speech with less nasal escape.
- 19 June 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (11) , 6155-6157
Brainstem stroke presenting with uncontrollable laughter: be alert when nobody else is laughing
- 19 June 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (11) , 6155-6157
Brainstem stroke presenting with uncontrollable laughter: be alert when nobody else is laughing
- 5 April 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (6) , 524-527
A cause of encephalopathy not to be missed
He had a 10-year history of type 2 diabetes mellitus and bilateral sensorineural hearing impairment, requiring hearing aids. Close family members had noted further hearing deterioration two weeks before admission, which was later confirmed by audiometry; this affected both sides symmetrically particularly at higher frequencies. His maternal grandmother also had hearing impairment. He did not smoke or drink alcohol and had not used illicit drugs.
- 5 April 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (6) , 524-527
A cause of encephalopathy not to be missed
He had a 10-year history of type 2 diabetes mellitus and bilateral sensorineural hearing impairment, requiring hearing aids. Close family members had noted further hearing deterioration two weeks before admission, which was later confirmed by audiometry; this affected both sides symmetrically particularly at higher frequencies. His maternal grandmother also had hearing impairment. He did not smoke or drink alcohol and had not used illicit drugs.
- 10 December 2021
- Published by BMJ in Practical Neurology
- Vol. 22 (3) , 257
The Spare Room